SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alteon (ALT) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Tomko who wrote (240)3/19/1998 8:52:00 PM
From: go_bucks  Read Replies (1) | Respond to of 318
 
ALTN has 17 millions shares outstanding and their CFO said
they have 29 million in cash. That works out to $1.7/share
already :)



To: Bill Tomko who wrote (240)3/19/1998 9:05:00 PM
From: Dr. John M. de Castro  Respond to of 318
 
The idea that better drugs may be in the pipeline is moot. If pimagidine does not pan out ALTN is history. There is no way that investors are going to fund a new drug all the way through these very expensive clinical trials after a pimagedine disaster. As pointed out, things may be better than appears at the moment. But, focus on the current Phase IIIs and their outcomes. That is what will determine if ALTN becomes profitable or a penny stock.

John de C


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News